BioSpace News Archive

GlaxoSmithKline’s PARP inhibitor Zejula has been approved for wider use in some cancers.

Targeted drug delivery is by no means an easy task, but luckily bioconjugation can be of great assistance.

MaxQ AI announced that its Accipio Ix™ and Accipio Ax™ intracranial hemorrhage detection software will be available on the Nuance® AI Marketplace, the first and largest portal with one-stop access to a wide range of AI diagnostic models from within the industry’s most widely used radiology reporting platform.

Synthetic biology company, Camena Bioscience, announces a significant breakthrough in DNA synthesis accuracy with the development of an innovative technology called gSynth™.

CluePoints, the premier provider of Risk-Based Study Execution and Data Quality Oversight Software for clinical trials, announced major expansion as it bolsters its offering with two new larger offices to accommodate its growing family of employees and contractors.

In the framework of the collaboration, Genedata delivers fully validated cloud-based enterprise solution for integration, management and analysis of clinical, biomarker, NGS, and digital pathology data from public and clinical studies to enable AI-driven development of next generation therapeutics.

Signant proud to take leadership role at 10th annual summit as key pioneers and thought leaders convene to advance the science and technology of CNS research

Acorda Therapeutics will terminate approximately 25% of its headcount as the company initiates a corporate restructuring only weeks after being snubbed by the U.S. Supreme Court over a patent appeal for multiple sclerosis drug Ampyra.

This morning’s approval from the U.S. Food and Drug Administration marks the 11th therapeutic indication for Botox, a product tent pole for Ireland-based Allergan.

MaxCyte, the global cell-based therapies and life sciences company, announces two presentations at the 5th Annual Cell & Gene Therapy Congress taking place 29-30 October in London, UK, which showcase the Company’s cell therapy technology.